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Abstract
Genome-wide association studies of the related chronic inflammatory bowel diseases (IBD) 
known as Crohn’s disease and ulcerative colitis have shown strong evidence of association to the 
major histocompatibility complex (MHC). This region encodes a large number of immunological 
candidates, including the antigen-presenting classical HLA molecules1. Studies in IBD have 
indicated that multiple independent associations exist at HLA and non-HLA genes, but lacked the 
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statistical power to define the architecture of association and causal alleles2,3. To address this, we 
performed high-density SNP typing of the MHC in >32,000 patients with IBD, implicating 
multiple HLA alleles, with a primary role for HLA-DRB1*01:03 in both Crohn’s disease and 
ulcerative colitis. Significant differences were observed between these diseases, including a 
predominant role of class II HLA variants and heterozygous advantage observed in ulcerative 
colitis, suggesting an important role of the adaptive immune response to the colonic environment 
in the pathogenesis of IBD.
Meta-analyses of genome-wide association studies (GWAS) have recently shown that 
Crohn’s disease (CD) (MIM266600) and ulcerative colitis (UC) (MIM191390) share the 
majority of the 163 known genetic risk factors for IBD, with the MHC being one of the 
notable exceptions4. Data from these GWAS, however, have had insufficient variant density 
to define the association signals within the MHC. Targeted studies of IBD with higher 
variant density within the MHC region but with modest sample sizes have indicated that 
multiple independent associations are likely to exist at human leukocyte antigen (HLA) 
genes and non-HLA genes, with the most consistent associations being to HLA class II loci, 
mainly HLA-DRB1 and HLA-DQB1, with some reports of association at the HLA-C class I 
locus and potentially also at non-HLA genes2,3,5–8. In the current study we generated high 
quality genotypes for 7,406 SNPs within the MHC region on a total of 18,405 patients with 
CD, 14,308 patients with UC and 34,241 controls subjects. Using this SNP data, we imputed 
and benchmarked the genetic variation within the class I (HLA-B, HLA-C, and HLA-A) and 
class II (HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-
DPA1 and HLA-DPB1) HLA genes at the level of classical HLA alleles and amino acid 
positions (please refer to the Online Methods).
As a first step to defining the nature of the association to CD and UC within the MHC, we 
performed univariate analyses of the SNPs, classical HLA alleles, and HLA amino acids. 
These analyses revealed a very large number of variants across the MHC region with 
significant association to these phenotypes (Fig. 1), with major peaks of association centered 
in and around the classical HLA genes, suggesting a role for classical HLA alleles in CD 
and UC risk. This observation is consistent with gene-based analyses, which show strong 
association at the HLA genes for both UC and CD (e.g. P<1×10−300 for HLA-DRB1 in UC) 
(Supplementary Table 1). In particular, these analyses demonstrated a role of HLA-DRB1 
that cannot be attributed to other HLA genes, with evidence of residual association in class I 
and class II regions (Supplementary Table 1). In order to be more quantitative, we 
calculated the variance explained by the class I and class II alleles. Whereas the contribution 
of class I and class II alleles are relatively equivalent in CD, not only is the overall impact of 
HLA on disease risk greater in UC, but the alleles in the class II region have nearly three-
fold greater impact than class I alleles (Fig. 2). Moreover, these analyses have revealed that 
classical HLA alleles explain three- to ten-fold more of the disease variance than that 
explained by the index SNPs that were previously identified (~3% vs ~0.3% in CD; ~6% vs 
~2% in UC) (Fig. 2).
Specifically, in our univariate analyses, the most significant association in CD is to HLA-
DRB1*01:03 (P<4×10−62, OR= 2.53), with a p-value over 10 orders of magnitude more 
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significant than the next best associated variants in the region. Importantly, HLA-
DRB1*01:03 has an effect in CD which is statistically independent from the other most 
associated variants in the MHC, as shown by reciprocal conditional logistic regression 
(Supplementary Fig. 1). In the UC univariate analysis the single most significant variant is 
a non-coding SNP (rs6927022, P<5×10−153, OR=1.49) near HLA-DQA1, previously 
identified in the recent meta-analysis of GWAS 4; while multiple additional variants show 
highly significant association, most are correlated to this top signal (Fig. 1 and 
Supplementary Fig. 2). Strikingly the next strongest independent association is to HLA-
DRB1*01:03, having a much greater OR (P<1×10−120, OR=3.63; Pcond<2×10−89, OR=3.06) 
(Supplementary Fig. 2). Reciprocal conditioning on HLA-DRB1*01:03 did not abolish the 
effect seen at rs6927022 (P<9×10−123, OR=1.43), indicating that these have mostly 
statistically independent effects in UC. Taken together, our analyses point to HLA-
DRB1*01:03 as likely being causal in both diseases, with additional causal alleles in the 
class II and class I regions. Given this observation, it is probable that additional alleles 
within HLA-DRB1 contribute to IBD risk.
We thus examined an HLA-DRB1-centric model and identified seven HLA-DRB1 alleles 
with independent effects on CD risk (study-wide significance threshold of 5×10−6) 
(Supplementary Table 2). Moreover, when controlling for these seven HLA-DRB1 alleles, 
we identified only a single additional class II allele (HLA-DPA1*01:03) independently 
associated with CD. Using the same conditional logistic regression framework for the 
analysis of the class I locus, we identified seven class I HLA alleles that are significantly 
associated with CD, after conditioning on the eight class II alleles (Fig. 3 and 
Supplementary Table 2). This HLA-DRB1-centric model explains about 2% of disease 
variance (Fig. 2). In UC, we identified a total of 12 HLA-DRB1 alleles, 1 HLA-DPB1 allele 
and 3 class I alleles (Supplementary Table 3) that can explain the association to the MHC 
and which account for about 5% of disease variance (Fig. 2).
As can be seen in Figure 3, for many of the alleles identified in the HLA-DRB1-centric 
model, a few other candidate alleles in class I or class II can be considered. In particular, 
multiple HLA-DRB1 alleles have equivalent associations at HLA-DQA1 and HLA-DQB1 
(e.g. HLA-DQA1*03:01 is equivalent to HLA-DRB1*04 and HLA-DRB1*09 alleles in UC) 
equally supporting a role for genetic variation within HLA-DQA1 and/or HLA-DQB1 in 
disease susceptibility, particularly for UC (Fig. 3). However, several of the alleles in these 
models, including HLA-DRB1*01:03, do not have any such proxies and thus are strong 
candidates for being causal (Fig. 3). Further dissection of these class II correlated signals for 
identifying potential causal alleles may only be feasible in admixed or ethnically diverse 
populations 9. Further refinement may also be possible by examining the impact of clinical 
sub-phenotype and associated autoimmune co-morbidities on observed associations, 
although functional studies will be needed to infer causality. For the present analysis we 
were able to assess the impact of colonic vs. non-colonic inflammation, and found that 
HLA-DRB1*01:03 is associated with colonic CD and that HLA-DRB1*07:01 is associated 
with the absence of colon involvement (Supplementary Fig. 3), in line with previous 
suggestions10. This explains the shared associations for CD and UC at HLA-DRB1*01:03 
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and strongly suggests that this allele is critically involved in determining the colonic 
immune response to local flora.
Given that classical HLA alleles consist of combinations of specific amino acids at multiple 
positions, we tested whether the association to disease could be better explained by single 
amino acid positions. Indeed we observed very strong association signals at many single 
amino acid variants in CD (e.g. five amino acids of HLA-DRβ at positions 67, 70 and 71) 
and in UC (e.g. 4 amino acid variants of HLA-DQα at positions 50 and 53 and 215 and 4 
amino acid variants in HLA-DRβ at positions 98 and 104) and also performed per position 
omnibus analyses that confirm the predominant association to HLA-DRβ position 11 in UC, 
as previously reported 5, and to HLA-DRβ position 70 in CD (Supplementary Tables 4–5 
and Supplementary Fig. 4). While the hypothesis of a positional effect is appealing, the 
interpretation of these position-based tests is not straightforward in the context of likely 
multiple causal alleles (Supplementary Note on amino acids, Supplementary Table 6 and 
Supplementary Fig. 5). Furthermore in this study the amino acid-based models did not 
capture the association at HLA-DRB1 in a more parsimonious way than the HLA allele-
based models (Supplementary Note on amino acids). To further explore the basis for the 
observed HLA associations, we performed three-dimensional protein structure modeling 
followed by analysis of the electrostatic properties of the binding groove of associated 
(P<10−4) and common (frequency>1%) HLA-DRB1 alleles. These analyses suggest that 
HLA-DR alleles associated with increased risk of UC and CD, share common structural and 
electrostatic properties within or near their peptide binding groove that are largely distinct 
from those of HLA-DR alleles associated with decreased risk of UC and CD (Fig. 4).
While we performed the primary analyses based on a dose effect model, our sample size 
allowed us to investigate the effects further, by testing for non-additive effects. In fact we 
found significant departure from additive effects in UC, but not for CD (Fig 5a–c). 
Specifically, we found evidence of decreased heterozygosity in UC patients for genotyped 
and imputed variants across the MHC and at HLA genes, mostly in class II (Supplementary 
Tables 7–8). This heterozygote advantage could be explained by an enrichment of dominant 
protective and recessive risk alleles11, that is absent or much less important in CD (Fig. 5 
and Supplementary Fig. 6). Notably, we also detected multiple overdominant effects in 
UC, the strongest of which is captured by HLA-DRB1*03:01 (Fig. 5, Supplementary Fig. 
6–7, and Supplementary Table 9). This allele is mostly found on the ancestral haplotype 
8.1, a relatively common (~5–10%) haplotype that is conserved in European populations and 
that is implicated in other immune diseases 12–14. The overdominance effect of this 
haplotype in UC is possibly due to the presence of both dominant protective and recessive 
risk alleles, which would be consistent with the reported recessive risk of this haplotype in 
the UC-related biliary disease primary sclerosing cholangitis (Supplementary Fig. 8–
9) 15,16. Analogous with an infectious paradigm 11, these data may suggest that decreased 
HLA class II heterozygosity may impair the ability to appropriately control colonic 
microbiota in UC.
Although there is a significant challenge in defining the causal alleles for CD and UC in the 
MHC given the LD structure in the region, a number of conclusions can be drawn regardless 
of the models tested. First, the high density mapping of this region in a large cohort revealed 
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the significant contribution of the MHC to disease risk, a contribution that is not apparent in 
the previous GWAS. Second, for both CD and UC it would appear that variation within 
HLA genes as opposed to variation in other genes within the MHC plays a predominant role 
in disease susceptibility. Third, while the contribution of class I and class II HLA variants to 
disease risk is relatively equivalent in CD, HLA class II variation plays a more important 
role in UC. Fourth, in contrast to the majority of non-MHC susceptibility loci being shared 
between CD and UC, most associated HLA alleles have a predominant role in either CD or 
UC, with very few having shared IBD risk Fig. 6). Finally, the decreased heterozygosity in 
UC suggests that the ability to recognize a broader set of antigens, potentially of colonic 
microbial origin, is important to mount protective immunity.
Online Methods
Genotype dataset
The cohorts used in the current study were collected from 15 countries across Europe, North 
America, and Australia, and have previously been described4. In total 19,802 CD cases, 
14,864 UC cases and 34,872 controls of European ancestries, from the International IBD 
genetics consortium (IIBDGC; www.ibdgenetics.org), were included in the study.
Genotyping of the IIBDGC cohorts was performed in 34 different batches across 11 
different genotyping centers, and additional genotyping data for 5,815 controls was obtained 
from the International MS Genetics Consortium (IMSGC)17. All participating centers 
received approval from their local and national institutional review boards, and informed 
consent was obtained from all participants in the study. All DNA samples included in the 
study were genotyped using the Immunochip custom genotyping array (Illumina, San Diego, 
California, USA)4,18.
Genotype calling and quality control
After an initial genotype calling using Illumina’s Bead Studio and a first stage of quality 
control, all data was centrally recalled using optiCall v.0.6.219. OptiCall clustering was 
performed for each batch separately, with a Hardy-Weinberg Equilibrium (HWE)-threshold 
of 1×10−15, HWE blanking disabled and a genotype call threshold of 0.7. HWE was 
calculated conditional on predicted ethnicity, and related individuals were removed from 
this calculation.
After recalling, a single unified QC procedure was performed across all genotyping batches, 
including the IMSGC controls. Variants that either failed the Hardy-Weinberg Equilibrium 
test in unaffected individuals, had different missing genotype rates in affected and 
unaffected individuals, or had significantly different allele frequencies across the batches 
based on false-discovery rate (FDR) threshold of 10−5 for each test were removed. We also 
removed variants that had missing genotype rate >2% across the entire collection, or > 10% 
in any single batch. Variants that only failed one QC criteria in a single batch were set to 
missing in the failed batch. Individuals were removed if they showed a missing genotype 
rate >2%, had a significantly higher or lower inbred coefficient (F) (plink)20 at FDR <0.01, 
and showed a high level of relation (PI_HAT ≥ 0.4) calculated on IBS distance between all 
individuals. The coefficient of inbreeding and inter-sample relationships were calculated on 
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a LD-pruned dataset of independent variants. In order to control for population stratification 
while avoiding the possible bias introduced by the enrichment of associated alleles in the 
dataset, principal components were computed on control samples, based on a set of 18,123 
independent (LD-pruned) SNPs across the Immunochip, and then applied to the affected 
samples. To generate the LD-pruned SNPs, we removed variants in long range LD and 
pruned the common variants (MAF>0.05) three times (plink20). Genomic inflation factor (λ) 
was estimated from a set of 3120 “null” SNPs (chosen based on GWAS of schizophrenia, 
psychosis and reading/mathematics ability), using different subset of principal components. 
Based on these and investigation of contribution of individual SNPs to the components 
(loadings), we selected to use the first five principal components to control for population 
stratification (Supplementary Fig. 11).
For the purpose of this study, the chr6:25Mb-34Mb region, encompassing MHC region, was 
extracted from the post-QC Immunochip dataset. In total, after QC, 18,405 CD cases, 14,308 
UC and 34,241 healthy controls subjects were successfully genotyped for 8,001 SNPs within 
the MHC region.
Imputation of missing genotype data
Missing genotype data, from failed genotype calls or failed QC in single batches, were 
imputed using the Beagle SNP imputation package(v.3.0.4); imputation was performed 
using only the high density information contained within the dataset, no external reference 
dataset was used21.
Imputation of HLA alleles
In order to avoid cohort specific asymmetry in the dataset, variants that failed QC in only 
one genotyping batch were removed before imputation of HLA alleles. Imputation of HLA 
alleles was done using two independent HLA imputation pipelines HLA*imp222 and 
SNP2HLA (v2)23; imputation of polymorphic amino acid positions and SNP variants was 
performed using SNP2HLA (v2). A set of additional SNP variants were also included using 
version 1 of SNP2HLA, which used a different reference dataset and imputed SNP variants 
not found in the SNP2HLA (v2) reference dataset.
Imputation accuracy
To benchmark HLA imputation results generated by HLA*IMP2 and SNP2HLA, we used 
two cohorts from the current study (Italian and Norwegian) for which classical HLA typing 
was available. The Italian dataset consisted of 450 ulcerative colitis cases and 280 controls 
for which 4-digit HLA types at HLA-A, HLA-B, HLA-C, HLA-DQB1 and HLA-DRB1 
generated by Sequence-based typing (SBT)24. The Norwegian dataset contained 244 
ulcerative colitis cases and 254 controls with 2-digit HLA types and a subset of 92 cases and 
250 controls with 4-digit HLA types at HLA-DRB1 generated at the Oslo University 
Hospital. We only considered individuals of whom both HLA alleles were successfully 
typed at 2- and 4-digit resolution at the locus under validation. For validation of HLA allele 
imputations, we compared imputation results of HLA*IMP2 and SNP2HLA to the lab-
derived types in a locus-specific and allele-specific manner. We calculated per locus 
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concordance (Supplementary Table 10) and sensitivity, specificity, positive predictive 
value, negative predictive value and accuracy for each allele (Supplementary Table 11).
Let’s denote true positives, true negatives, false positives and false negatives by TP, TN, FP 
and FN, respectively. Given our analyses were performed using expected allele doses from 
posterior probabilities, we used the expected doses for computation:
where xi and yi are respectively the typed and imputed dose for individual, and the sum over 
all individuals gives the TP, FP, TN and FN (Supplementary Table 11). For a given HLA 
allele, we calculated sensitivity, specificity, positive predictive value, negative predictive 
value and accuracy using the usual definitions:
For a given locus, we calculated the concordance as TPall/(total number of chromosomes) 
(Supplementary Table 10).
Final dataset
As an additional QC step, we performed manual cluster inspection for any genotyped SNPs 
in the region tagging (r2>0.8) imputed SNPs, amino acid variants and HLA alleles reported 
in our proposed models for CD and UC.
In order to not duplicate HLA alleles in our dataset, and given the mostly equivalent 
imputation quality of the 2 pipelines, we opted to keep HLA imputations for HLA-A, HLA-B, 
HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 derived from 
the SNP2HLA pipeline since amino acid and additional SNPs were also obtained from this 
pipeline, whereas the HLA allele information for the HLA-DRB3, HLA-DRB4, and HLA-
DRB5 genes were obtained from the HLA*imp2 pipeline.
Genotyped SNPs variants, as well as imputed SNPs, HLA alleles and amino acid variants at 
polymorphic amino acid positions were combined into a single dataset for analysis. Variants 
with a minor allele frequency of less than 0.05% in controls and variants showing 
imputation quality (INFO) score <0.5 were removed from the analyses. The final dataset 
contained 8,939 SNP variants, 138 4-digit resolution HLA alleles, 90 2-digit resolution HLA 
alleles and 741 single amino acid variants.
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Heterogeneity
In order to evaluate heterogeneity of effects and allele frequencies between subgroups of 
different European ancestry, we clustered the individuals into relatively large population 
subgroups. These clusters were determined using k-means on the principal components. 
Based on the decline within cluster sum of squares, we determined that the optimal choice 
for the number of clusters (k) was in a range of 6–10. For each value of k in this range, we 
compared the clustering obtained to self-reported country of origin, when available. The 
objective was to be able to identify known population structures, while keeping 
homogeneous group in a single cluster. Based on these criteria, we stratified the dataset into 
9 clusters (Supplementary Fig. 12). For every reported variant, we evaluated and illustrated 
heterogeneity of effect sizes between these 9 clusters using forest plots (Data on 
heterogeneity of effects is available on http://www.medgeni.org/goyette_nature_gen_2015).
Association testing and conditional analyses
Unless otherwise stated, all analyses were corrected for five principal components and 
performed in R (v 2.15.2) on expected allele counts (additive dose from posterior 
probability)(see Supplementary Tables 4, 12 and 13 for primary univariate association 
results for single amino acid variants, SNP and HLA alleles respectively). Also, 4-digit HLA 
alleles were prioritized over 2-digit alleles in the final selection of association signals 
included in our models. We calculated the threshold for statistical significance in our study 
at p<5×10−6 for a study-wide type 1 error rate of 5% with 9,852 independent tests.
Given the imputed nature of the HLA allele data within our dataset, complexity of signals 
and burden of dimensionality, a standard forward conditional logistic regression approach 
was avoided. We opted instead to identify all HLA alleles showing study-wide significant 
association across the MHC region, in the primary univariate association dataset, and 
evaluate their independent effects through single pair-wise reciprocal conditional logistic 
regression (Supplementary Tables 2–3). This approach allowed the identification of 
independent association signals, composed either of single HLA alleles or groups of 
equivalent alleles (Fig. 3).
Gene based analyses (omnibus)
We tested the association to phenotypes at each HLA gene using logistic regression under an 
additive model of effect, including all 4-digit alleles with a frequency greater than 0.5%. 
Evidence of association at the gene is given as the p-value of the likelihood test for this 
regression model versus the null model (including only principal components). Evidence of 
association at a given gene, conditional on other HLA genes, is given as the p-value of the 
likelihood ratio test for the full model (including all HLA alleles) versus the partial model 
(without including the alleles at the given gene). In a similar fashion, we also tested the 
remaining association at each HLA gene, conditional on our final set of associated alleles 
(final model). To be noted, the different HLA genes have different number of distinct 
alleles, thus variable level of complexity (degrees of freedom) for the model and the 
interpretation of these gene-based tests is not straightforward in the context of likely 
multiple causal alleles (see the Supplementary Note on amino acid).
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Variance explained (pseudo R2)
In order to represent the importance of genetic variation in the MHC for CD and UC, we 
computed an estimate of variance explained for different models. Variance explained is not 
well defined for binary outcomes and many different metrics exist to represent it25. Given 
the correlation between the variants in the MHC, we computed McKelvey Zavoina’s pseudo 
R2 on the logit scale26. This metric can be computed using correlated variables and is 
independent of disease prevalence. Let β be the vector of fitted coefficients from logistic 
regression and S the estimated covariance matrix of the predictor, the McKelvey Zavoina’s 
pseudo R2 is then given by:
To be noted, this estimation of variance explained shouldn’t be directly compared to values 
given by other metrics or to heritability estimates based on Gaussian liability. We computed 
the variance explained by a regression model including all the HLA alleles with a frequency 
greater than 0.5%. We did the same separately for HLA alleles within class I and class II. 
Variance explained by class I, after inclusion of class II, was computed as the improvement 
in R2 for the full model (all HLA alleles), compared to class II only. This difference in R2 
estimates the specific contribution of class I to the total variance explained that cannot be 
attributed to class II alleles. We did the same for class II. In order to be able to compare our 
results to the SNPs identified by the GWAS4, we computed R2 for the published GWAS 
index SNP in the MHC for CD and UC.
Subphenotype analyses
The IIBDGC has collected detailed subphenotype information for a subset of samples 
included in this study. These phenotypes include: demographics, disease location and 
behavior in CD, disease extent in UC, surgery and primary sclerosing cholangitis (PSC). 
Quality control of this subphenotype information and genotype-phenotype association 
testing has been performed in the context of another project from this IIBDGC (personal 
communication with Charlie Lee). In the context of this fine-mapping project, we 
considered disease location in CD and PSC in UC to evaluate the impact of disease 
heterogeneity. Association tests were performed within subset of samples with known 
subphenotype.
Non-additive effects, heterozygote advantage and overdominance
We tested evidence of non-additive effects at each variant using a logistic regression 
including terms for additive and non-additive effect, as described below. Rare variants with 
minor allele frequencies below 5% were excluded from this analysis, given that the very low 
number of homozygote precludes the evaluation of the model. For this particular analysis, 
we used best guess genotype data, unless otherwise stated. We computed evidence of non-
additive effect as the p-value of the Wald statistic for the dominance term. We also 
computed the evidence of association for an allele under the general model using the 
likelihood ratio test.
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Suppose a genetic variant with alleles G and g. The genotypes (GG, Gg, gg) can be coded as 
u = (1, 0, −1) and v = (0, 1, 0), respectively. In this context, u = dose - 1 and v = 1 − |u|. 
The effect of a specific genotype is then given as au + dv, where a and d are respectively the 
additive and dominance effect, as estimated by logistic regression. This parameterization can 
be generalized to expected allele counts (additive dose from posterior probability).
Under this parameterization, the effects of the genotypes GG, Gg and gg are given by a, d 
and −a, respectively. A strictly additive model would be d = 0 and a ≠ 0, while a dominant 
or recessive model would be d = a or d = −a. If the dominance term has a higher protective 
effect than the additive term, that is d < −|a|, the model is one of overdominance, where 
being a heterozygote provides protection, compared to both homozygotes.
For each HLA gene, we also tested for evidence of heterozygote advantage. We coded each 
individual as homozygote or heterozygote at the gene, as determined from the imputed 2-
digit and 4-digit alleles. Association of phenotype and zygosity at each gene was tested 
using logistic regression. Evidence of association is given as the p-value of the likelihood 
test.
Pairwise comparisons of common 2-digit alleles at HLA-DRB1 were conducted to better 
understand the non-additive effects (Supplementary Table 9). For each pair or alleles, 
analysis was constrained to the subset of individual carrying only these two alleles as 
homozygotes or heterozygotes. Genotype effects were evaluated within each subset. 
Overdominance was tested as heterozygote vs the lowest risk homozygote. Heterozygote 
advantage was tested as heterozygote vs the pooled homozygote. Non-additive effect was 
tested based on the dominance term, as described previously.
Comparative structural modeling of HLA-DR alleles
Comparative structure models for all HLA-DR alleles associated with UC or CD, and of all 
common HLA-DR alleles (population frequency >1%), were generated using the program 
MODELLER27. Templates for comparative structure modeling were identified by querying 
the RCSB Protein Database28 using the sequence of HLA-DRB1*01:01 and the DELTA-
BLAST algorithm, for humans (Taxonomy ID: 9606, E-value threshold of 0.05). Of 36 
templates identified, 10 crystallographically resolved HLA-DRB1 structures (PDB codes: 
4MD5, 1FV1, 1KLU, 3PDO, 1D5M, 1JH8, 4MDI, 3L6F, 4I5B, 2IPK) were retained, which 
had high resolution (<2.5 Å) and favorable markers of structural quality (Ramachandran 
plot, DOPE, Verfiy3D and WHAT_CHECK scores)29–32. The sequences of the extracellular 
domain of target HLA molecules were retrieved from the EBI sequence database (ftp://
ftp.ebi.ac.uk/pub/databases/ipd/imgt/hla/) and aligned using Clustal W2 using the BLOSUM 
matrix and the Neighbor Joining clustering algorithm and manually adjusted as indicated33. 
The modeled peptide was standardized to an alanine 12-mer, which was removed prior to 
calculating protein electrostatics to allow comparison of the electrostatic potential within the 
peptide-binding groove.
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Electrostatic potential calculations
Atom charges and radii were assigned and side-chains protonated for pH 7.4 using the 
PARSE force field in PDB2PQR34. Protein electrostatic potential was calculated by solving 
the linearized Poisson-Boltzmann equation in APBS for a cubic grid of 353 points at a 
spacing of 0.33 Å35. Other parameters were set as follows: ionic solution of 0.15 M of 
univalent positive and negative ions; protein dielectric of 2; solvent dielectric of 78; 
temperature of 310 K; and a probe radius of 1.4 Å. HLA class II molecules typically make 
contact with nine amino acid residues of the presented peptide; of these, 7 peptide residues 
(at peptide positions 1, 2, 3, 4, 6, 7 and 9) make contact within the peptide binding groove36. 
Peptide residues at positions 5 and 8 are elevated away from the peptide-binding groove. For 
comparison of the electrostatic potential of the peptide-binding groove, radii were chosen so 
that the space around each coordinate encompassed all side chain atoms of the relevant 
peptide amino acid residue; the electrostatic potential within 1Å from the molecular surface 
of the HLA molecule was not examined.
The peptides of the template HLA structures were used to define the geometric average 
coordinate of the positions of the side chain atoms of peptide amino acid residues 1, 2, 3, 4, 
6, 7 and 9. The electrostatic potential within a 3.5–5 Å radius from each coordinate was 
considered for comparison of the electrostatic properties of the peptide-binding groove 
among HLA-DR alleles (Supplementary Fig. 10). For comparison of the electrostatic 
potential around amino acid positions 67, 70 and 71, (associated to both UC and CD in 
different analyses; Supplementary Tables 4–6), the geometric average coordinate of the 
positions of these amino acids’ side chain atoms was calculated and the electrostatic 
potential within a 5 Å radius from this coordinate was considered for comparisons among 
different alleles. Electrostatic potential comparisons were performed using the Hodgkin’s 
index as described previously27,28 in a pairwise, all-versus-all, fashion to produce a distance 
matrix37,38. Distance matrices were displayed as a symmetrical heatmap with re-ordering 
such that electrostatically similar alleles are clustered together, according to the dendrogram 
(Supplementary Fig. 13). A pooled heatmap was created using the Euclidian distance 
between the individual distance matrices from the 7 peptide-binding groove regions (Fig. 
4a). Heatmaps were created for electrostatic potential comparisons at individual regions of 
the HLA-DR molecule (7 regions in the peptide-binding groove and one region defined by 
amino acid residues 67, 70 and 71, as detailed above) (Fig. 4b).
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Figure 1. Primary univariate association analyses of CD and UC
Univariate association analysis results for 8,939 SNPs (dark grey) (Supplementary Table 
12), 90 2-digit and 138 4-digit resolution HLA alleles (yellow) (Supplementary Table 13), 
as well as 741 single amino acid variants (red) (Supplementary Table 4) in the MHC 
region are shown for 18,405 CD cases and 14,308 UC cases (with 34,241 common control 
subjects). Given that previous genetic analyses have identified distinct effects in the MHC 
for CD and UC, with different non-correlated alleles identified in each disease, we opted to 
perform the finemapping analyses for CD and UC separately. (a) The primary univariate 
association analysis in CD reveals over 1,789 markers showing study-wide significant 
association (P<5×10−6) across the MHC, including 32 4-digit resolution classical HLA 
alleles (Fig. 3 and Supplementary Table 2). The single most significant variant for CD is 
HLA-DRB1*01:03 (P=3×10−62, OR= 2.51). (b) The primary univariate association analysis 
in UC reveals over 2,762 markers showing study-wide significant association across the 
MHC, including 50 4-digit resolution classical HLA alleles (Fig. 3 and Supplementary 
Table 3). The single most significant variant for UC is rs6927022 (P=8×10−154, OR= 1.49) 
while the best HLA allele is HLA-DRB1*01:03 (P=3×10−119, OR=3.59); each acting 
independently. Twenty-nine SNPs and 9 amino acid variants surpass HLA-DRB1*01:03 as 
the next most significant variants in the primary analysis however all of these are correlated 
to rs6927022 and their significance is dramatically reduced by conditional logistic 
regression.
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Figure 2. Variance explained by 4-digit HLA alleles in CD and UC
Proportion of variance explained on a logit scale (McKelvey and Zavoina’s Pseudo R2, see 
Online Methods) for different models in CD (left) and UC (right). The top boxes show the 
variance explained by previously identified GWAS index SNPs within the MHC4. The 
middle boxes illustrate the variance explained by HLA models including all 4-digit alleles of 
frequency > 0.5% (126 alleles in CD and UC) and models restricted to 4-digit alleles within 
either class I (63 alleles) or class II regions (63 alleles), respectively. The Venn diagram 
illustrates the proportion of variance explained that is unique to class I, class II or shared. 
The bottom boxes indicate the variance explained by the proposed HLA models (15 and 16 
alleles in CD and UC, respectively). To be noted, these estimations of variance explained 
were performed on the logit scale for practical reasons, and should not be directly compared 
to heritability estimates computed on the (Gaussian) liability scale.
Goyette et al. Page 19
Nat Genet. Author manuscript; available in PMC 2015 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3. Correlated association signals at HLA alleles support potential alternate association 
models for both CD and UC
Equivalence of effect at the different study-wide significant associated 4-digit HLA alleles is 
shown for (a) CD and (b) UC. The structures illustrated in the figure are not classically 
defined haplotype structures, but were identified entirely based on the correlation of signal 
defined through pairwise reciprocal conditional logistic regression analyses (see 
Supplementary tables 2 and 3); although such correlations are clearly dependent on the 
underlying haplotypic structure of the region. Alleles identified as primary tags for 
independent association signals in our HLA-DRB1 focused models are shown in light blue 
boxes, while alternate alleles with equivalent effects are shown in grey boxes. Alleles in 
white boxes show study-wide significant secondary effects that can be explained entirely by 
the selected HLA alleles. Alleles at the HLA-DRB3, -DRB4 and -DRB5 genes were omitted 
in order to simplify the display; many of the alleles at these genes show high frequency and 
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as such are correlated to many different alleles (both risk and protective) at the other class II 
genes. Of note, the HLA-DRB4*null allele is the second strongest associated allele in UC 
(see Supplementary table 3).
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Figure 4. HLA-DR peptide binding groove electrostatic properties and risk of IBD
The electrostatic potential of all HLA-DR alleles associated with UC or CD, and of all 
common HLA-DR alleles (frequency >1%), was calculated. HLA-DR alleles associated 
with increased or decreased risk of IBD at study wide-significance level (P< 5×10−6) are 
shown in dark red or dark blue, respectively. Respective risk associations at suggestive level 
(1×10−4<P<5×10−6) are shown in pale red and pale blue. Electrostatic potential comparisons 
among HLA-DR molecules were performed in a pairwise, all-versus-all, fashion (see Online 
Methods) to produce distance matrices that are displayed as symmetrical heatmaps (scale 
ranges from 0 [identical] to 1 [maximum difference]). (a) The electrostatic potential in seven 
regions within the peptide binding groove (see Online Methods and Supplementary Fig. 
10), which interact with the presented peptide, were compared among the HLA-DR alleles 
and pooled onto a single Euclidian distance matrix. The distance-based clustering identifies 
four clusters, with an enrichment of risk alleles in two of these. Comparison of the 
electrostatic potential at individual peptide binding groove regions is shown in 
Supplementary Fig. 13. (b) Heatmap representing electrostatic potential differences among 
the HLA-DR alleles at a spherical region that encompasses amino acid residues 67, 70 and 
71 of the HLA-DRβ chain (associated with risk for UC and CD; Supplementary Table 13). 
The distance-based clustering identifies two clusters that correlate with directionality of 
effect in IBD.
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Figure 5. Non-additive effect models in CD and UC
Evidence for non-additive effect of common variants (frequency >5%) across the MHC 
tested under a general model of additive and dominance effects (Online Methods) in CD 
(a,b) and UC (c,d). The p-values and directionality for departure from additive effect 
(dominance term) are represented on the y-axis (a,c). HLA alleles and amino acids variants 
are in yellow and red respectively, while SNPs are represented in dark grey. Variants with 
non-significant (P>5×10−6) dominance term are plotted in less pronounced colors. A clear 
enrichment for lower risk in heterozygotes is observed in UC (c) as suggested by the large 
number of significant negative dominance term (lower part of the plot). This effect is absent 
in CD (a), or much less important. The dominance term OR is illustrated (y-axis) versus the 
additive term (x-axis) (b,d). Protective and risk minor alleles are shown on the left and right 
sides of the plot respectively. Strictly recessive or dominant variants are expected to fall on 
the diagonals, while strictly additive variants lay on or close to the x-axis. The y-axis is the 
expected position for pure over/under dominance. In UC (d), many alleles fall into the 
region of the plot for protective dominant, risk recessive or overdominance (blue triangle) 
(see Supplementary Table 9 for pairwise comparison of HLA-DRB1 alleles). These non-
additive effects are observed for many variants in UC (c,d) (e.g HLA-DRB1*03:01 and 
HLA-DQB1*02:01) but are mostly absent in CD (a,b); notable exception being the HLA-
B*08 allele (Supplementary Fig. 6).
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Figure 6. Comparison of odds ratio in CD and UC for HLA alleles identified from HLA-focused 
models
Odds ratio (OR) from the primary univariate association analyses in CD and UC for all 
alleles identified in the HLA-focused models of CD and/or UC are presented with 95% 
confidence intervals (a). Odds ratio for CD and UC are in blue and red respectively; darker 
colors indicate study-wide significant effect (P<5×10−6), lighter colors indicate nominal 
significance level (0.05>P 5×10−6) and white indicates non-significance (P 0.05) (for 
specific effect and significance values refer to Fig. 3 and Supplementary Tables 2 and 3). 
Allele HLA-B*52:01 is indicated for UC in place of the equivalent HLA-C*12:02 to 
simplify the display of this shared signal. For the same HLA alleles, odds ratio (with 95% 
confidence intervals) for an IBD analysis are plotted against the odds ratio for the CD versus 
UC analysis with the IBD risk allele as the reference (b). Empty circles represent variants 
where the absence of the allele is the reference. Alleles identified as significant in CD or UC 
only are plotted in blue and red, respectively. Variants identified as significant in both are 
shown in purple. To be noted, HLA-DRB1*07:01 and HLA-DRB1*13:02 have opposite 
direction of effect between CD and UC. Shared association signals are expected to fall in the 
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upper triangle of the plot. Most variants fall outside of this region, highlighting the 
difference between CD and UC in the MHC.
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